Use of pamidronate in chronic and acute bone loss conditions

Medicina

Volumn 57, Issue SUPPL. 1, 1997, Pages 101-108

  Devogelaer, Jean Pierre ^a   De Deuxchaisnes, Charles Nagant ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

osteogenesis imperfecta; osteoporosis; pamidronate

Indexed keywords

PAMIDRONIC ACID;

BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; FRACTURE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEODYSTROPHY; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; SHORT SURVEY;

ACUTE DISEASE; BONE DENSITY; BONE RESORPTION; CHRONIC DISEASE; DIPHOSPHONATES; FEMALE; HUMANS; MALE; OSTEOGENESIS IMPERFECTA; OSTEOPOROSIS; REFLEX SYMPATHETIC DYSTROPHY;

EID: 9844219752     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (24)

1. Nagant de Deuxchaisnes C, Devogelaer JP, Esselinckx W, Depresseux G, Rombouts-Lindemans C, Huaux JP. Non-hormonal treatment of osteoporosis. Brit Med J, 1983; 286:1648.
2. Huaux JP, Devogelaer JP, Brasseur JP, Nagant de Deuxchaisnes C. Effect of the diphosphonate APD on dual photon absorptiometry in involutional osteoporosis, pp. 998-999. In: Norman AW, Schaefer K, Grigoleit H, v. Herrath D (eds.) Vitamin D. Chemical, Biochemical and Clinical Update. Walter de Gruyter, New York 1985.
3. Devogelaer JP, Huaux JP, Nagant de Deuxchaisnes C. Bisphosphonate therapy with APD in involutional osteoporosis with vertebral crush fractures, pp. 950-952 In: Christiansen C, Johansen JS, Riis BJ (eds.) Osteoporosis 1987. Viborg, 1987. Norhaven A/S.
4. Devogelaer JP. Nagant de Deuxchaisnes C. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate): non-linear increase of lumbar bone mineral density, pp, 1507-1509. In: Christiansen C, Overgaard K (eds). Osteoporosis 1990. Aalborg, 1990. Handelstrykkeriet Aalborg ApS.
5. Devogelaer JP. Nagant de Deuxchaisnes C, Libanati C, Baylink D. Bone mass and remodeling changes induced by intravenous pamidronate with or without sodium fluoride therapy in osteoporosis. Bone 1995, 16 (suppl): 198S.
6. Devogelaer JP, Triki R, Depresseux G, Nagant de Deuxchaisnes C. Remanent effect of pamidronte on bone metabolism in osteoporosis. J Bone Min Res 1994; 9 (suppl. 1): S329.
7. Baron R, Gertner JM, Lang R, Vignery A. Increased bone turnover with decreased bone formation by osteoblasts in children with osteogenesis imperfecta tarda. Pediatr Res 1983; 17: 204-207.
8. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 1987; 16:360-363.
9. Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C. Radiological and absorptiometric manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta, pp. 953-955. In: Christiansen C, Johansen JS, Riis BJ (eds.) Osteoporosis 1987. Viborg, 1987. Norhaven A/S.
10. Devogelaer JP, Nagant de Deuxchaisnes C, Malghem J, Maldague B. Cyclical intermittent therapy with APD in a child with osteogenesis imperfecta: a 3-year follow-up of 7 cycles. Evidence of fading away of the oldest radio-opaque metaphyseal bands, pp, 1515-1517. In: Christiansen C, Overgaard K (eds). Osteoporosis 1990. Aalborg, 1990 Handelstrykkeriet Aalborg ApS.
11. Bishop NJ, Lanoue G, Chabot G, Travers R, Glorieux FH. Clinical and bone densitometric improvement after pamidronate infusion in children with severe osteogenesis imperfecta. J Bone Miner Res 1996; 11 (suppl. 1):S251.
12. Serre H, Simon L, Claustre J, Sany J. Formes cliniques des algodystrophies sympathiques des membres inférieurs. Rhumatologie 1973; 23:43-54.
13. Genant HK, Kozin F, Bekerman C, McCarty DJ, Sims J. The reflex sympathetic dystrophy syndrome. A comprehensive analysis and using fine detail radiography, photon absortiometry and bone and and joint scintigraphy. Radiology 1975; 117:21-32.
14. Doury P, Dirheimer Y, Pattin S (eds). Algodystrophy, diagnosis and therapy of a frequent disease of the locomotor apparatus. Springer Verlag. New York 1981.
15. Devogelaer JP, Dall'Armellina S, Huaux JP, Nagant de Deuxchaisnes C. Dramatic improvement of intractable reflex sympathetic dystrophy syndrome by intravenous infusions of the second generation bisphosphonate APD. J Bone Miner Res 1988; 3 (suppl.1):S122.
16. Valkema R, Vismas FJFE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM. Maintained improvement in calcium balance and bone mineral contents in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989; 5: 183-192.
17. Reid IR, Wattie DS, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 1595-1599.
18. Papapoulos SE, Landman JO, Bijvoet OLM, et al. The use of bisphosphonates in the treatment of osteoporosis. Bone 1992; 13:S41-S49.
19. Reid IR, Heap SW, King AR, Ibbertson HK. Two-year follow-up of bisphosphonate (APD) treatment in steroid-induced osteoporosis. Lancet 1988; ii:1144.
20. Devogelaer JP, Boutsen Y, Nagant de Deuxchaisnes C. A randomized controlled trial of APD (disodium pamidronate) given intravenously with and without sodium fluoride in involutional osteoporosis, pp, 1504-1506. In: Christiansen C, Overgaard K (eds). Osteoporosis 1990. Aalborg, 1990. Handelstrykkeriet Aalborg ApS.
21. Kanis JA, McCloskey EV, Sirtori P, et al. Rationale for the use of clodronate in osteoporosis. Osteoporosis Int 1993; 3 (suppl.2): S23-S28.
22. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996;18:141-150.
23. Devogelaer JP. Clinical use of bisphosphonates. Curr Opin Rheumatol 1996;8:384-391.
24. Delmas PD, Vergnaud D, Ariot ME, Pastoureau P, Meunier PJ, Nilssen MHL. The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption in inhibited by the bisphosphonate tiludronate-ls activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 1995; 16:603-610.